Marginal Zone Lymphoma treatment market is projected at a significant CAGR of 6.05% during the forecast period (2021-2030), as per DelveInsight

Increase in patient pool, expected entry of emerging therapies, and deeper penetration of these drugs in 7MM are key factors in driving Marginal Zone Lymphoma market 

LAS VEGAS, Feb. 9, 2021 /PRNewswire/ -- DelveInsight's "Marginal Zone Lymphoma (MZL) Market" report provides a complete comprehension of the Marginal Zone Lymphoma,  historical and forecasted epidemiology and the MZL market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Marginal Zone Lymphoma market report also proffers an analysis of recent MZL treatment practice/algorithm, market drivers, market barriers and unmet medical needs. 

Some of the highlights of Marginal Zone Lymphoma Market Research Report

• In May 2019, the FDA approved lenalidomide (Revlimid) in combination with a rituximab product for previously treated follicular lymphoma (FL) and previously-treated MZL. Moreover, in December 2019, the European Commission approved Revlimid (lenalidomide) combined with rituximab to treat adult patients with previously treated Marginal Zone Lymphoma. The drug is not being approved in Japan but is expected to get launched in the forecast period 2020–2030 and hence is an emerging therapy for Japan. 
• Imbruvica (ibrutinib) by AbbVie/Janssen Biotech is a first-in-class, oral, once-daily therapy that inhibits a protein called Bruton's tyrosine kinase (BTK). In January 2017, the USFDA approved Imbruvica (ibrutinib) for the treatment of patients with relapsed/refractory (R/R) Marginal Zone Lymphoma, who require systemic therapy and have received at least one prior anti-CD20-based therapy.
• Marginal Zone Lymphoma market is expected to grow due to factors like an increase in the patient pool, expected entry of emerging therapies such as Ublituximab, Duvelisib, Umbralisib (TGR-1202), and deeper penetration in the 7MM. 
• Several pharmaceutical key players such as TG Therapeutics, Bayer, Roche Pharma, Gilead Sciences, Merck, Cellectar Biosciences, Innovent Biologics, Bristol-Myers Squibb, AstraZeneca, Nordic Nanovector, AbbVie, InnoCare Pharma, ArQule, Verastem, Secura Bio, BeiGene, MEI Pharma, NantKwest, ImmunityBio, Loxo Oncology, Eli Lilly, TriSalus Life Sciences, and many others have taken the initiatives to meet the unmet needs of the present situation of the MZL market.

For additional information on Market Impact by Therapies, visit: Marginal Zone Lymphoma Market Forecast Analysis 

Marginal Zone B-cell lymphoma is a group of indolent Non-Hodgkin lymphoma (NHL) B-cell lymphomas that account for approximately 5‒17% of all NHL cases. The total Non-Hodgkin lymphoma incident population in the 7MM was estimated to be 174,941 in 2020. Out of these, the total Marginal Zone Lymphoma incident population in the 7MM was 22,268 in the same year. 

The Marginal Zone Lymphoma Market Report provides historical as well as forecasted epidemiological analysis segmented into: 

• Total incident cases of Non-Hodgkin lymphoma (NHL) 
• Total incident cases of Marginal Zone Lymphoma (MZL)
• Gender-specific incident cases of MZL 
• Subtype-specific incident cases of MZL
• Stage-specific incident cases of MZL

Review a sample report for more insights @ Marginal Zone Lymphoma Market Insight 

Marginal Zone Lymphoma Treatment Market

Treatment selection for an MZL patient depends on the type, stage, and location of the disease. The total MZL market is categorized into three types based on the line of therapies, first-line, second-line, and third-line of therapies. The first line treatment comprises only the supportive therapies, including rituximab monotherapy, R-CHOP/R-CVP, rituximab plus bendamustine, cytotoxic chemotherapy, antiviral therapy for hepatitis C infection, Antibiotic/PPIs.

In May 2019, the FDA approved lenalidomide (Revlimid) combined with a rituximab product for previously treated follicular lymphoma (FL) and previously-treated MZL. Moreover, in December 2019, the European Commission approved Revlimid (lenalidomide) in combination with rituximab for the treatment of adult patients with previously treated MZL. The drug is not being approved in Japan but is expected to get launched in the forecast period 2020–2030 and hence is an emerging therapy for Japan.

Revlimid is an immune-modulating therapy with proven anti-myeloma effects. The drug is an oral therapy that was shown to work in 3 ways in animal models and in vitro, it aids the immune system to identify and eradicate myeloma cells. It targets and destroys myeloma cells and helps prevent new myeloma cell growth by starving them of blood. 

Several pharmaceutical key players have taken the initiatives to meet the unmet needs of the present situation of the MZL market. Some of the key players are in the late and mid clinical development stages with their leading drug candidates. MZL pipeline possesses potential drugs as monotherapies as well as combination therapies. 

Marginal Zone Lymphoma Emerging Therapies Along with Key Players 

• Umbralisib (TGR-1202): TG Therapeutics
• Aliqopa (Copanlisib): Bayer
• Ublituximab: TG Therapeutics
• Obinutuzumab: Roche Pharma
• Yescarta (axicabtagene ciloleucel): Gilead Sciences
• Keytruda (Pembrolizumab): Merck Sharp & Dohme
• CLR 131: Cellectar Biosciences
• Parsaclisib: Innovent Biologics
• Nivolumab (Opdivo): Bristol-Myers Squibb
• Calquence (acalabrutinib): Astrazeneca
• Betalutin (177Lu-satetraxetan-lilotomab): Nordic Nanovector
• Navitoclax (ABT-263): AbbVie
• Orelabrutinib (ICP-022): InnoCare Pharma
• M7583: Merck KGaA
• ARQ 531: ArQule/Merck
• Duvelisib: Verastem/Secura Bio
• Zanubrutinib: BeiGene
• Zandelisib: MEI Pharma
• ALT-803: NantKwest/ImmunityBio
• LOXO-305: Loxo Oncology/Eli Lilly
• SD-101: TriSalus Life Sciences

And several others. 

Concluding thoughts on Marginal Zone Lymphoma Market Growth

Marginal Zone Lymphoma Market Drivers

• Awareness about the disease - Increased public awareness creates a lucrative opportunity to innovate therapeutics to drive MZL market.
• The rise in MZL cases - A better understanding of each subtype's molecular events is increasing day by day. 
• Research and development - Growing research and development increase the demand for better diagnosis and MZL treatment options. 
• Pipeline Advancement - A large number of agents are showing promising activity in MZL because of recent advances in a better understanding of the drug. 

Marginal Zone Lymphoma Market Barriers

• Diagnostic challenges - Some patients develop resistance to the drug rituximab and do not respond well to the therapy. Diagnostic options are much needed to improve the Marginal Zone Lymphoma prognosis and outcomes for patients. 
• Adverse effects of current treatment - The drugs are hampered by specific adverse effects coupled with patent expiration. Splenectomy and chemoimmunotherapy used in the treatment of MZL bear increased risks of complications in older patients. 

Scope of the Marginal Zone Lymphoma Market Insight  

• Geography Covered: 7MM - The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan
• Study Period: 4-year historical and 10-year forecasted analysis (2017-2030)
• Marginal Zone Lymphoma Markets Segmentation: By Geographies and By Marginal Zone Lymphoma Therapies (Historical and Forecasted, Current and Upcoming) 
• Leading Companies investigating its candidates for Marginal Zone Lymphoma: TG Therapeutics, Bayer, Roche Pharma, Gilead Sciences, Merck, Cellectar Biosciences, Innovent Biologics, Bristol-Myers Squibb, AstraZeneca, Nordic Nanovector, AbbVie, InnoCare Pharma, ArQule, Verastem, Secura Bio, BeiGene, MEI Pharma, NantKwest, ImmunityBio, Loxo Oncology, Eli Lilly, TriSalus Life Sciences, and several others.
• Analysis: Comparative and conjoint analysis of emerging therapies, Attribute Analysis
• Case Studies
• KOL's Views
• Analyst's View

Request for a Webex demo of the report @ Marginal Zone Lymphoma Market Size 

Table of Contents 

Browse detailed TOC with charts, figures, tables @ Marginal Zone Lymphoma Therapeutic Market 

View Related Reports       

• Marginal Zone Lymphoma Epidemiology Forecast Analysis 

DelveInsight's Marginal Zone Lymphoma - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology.

• Morquio Syndrome Market Analysis

DelveInsight's Morquio Syndrome Market Insights, Epidemiology and Market Forecast - 2030 report provides detailed insights on historical and forecasted epidemiology. 

• Diabetes Market Analysis 

DelveInsight's Diabetes Market Insights, Epidemiology and Market Forecast - 2030 report provides thorough insights on epidemiology and market trends.

• Buerger's Disease Market Analysis 

DelveInsight's Buerger's Disease Market Insights, Epidemiology and Market Forecast - 2030 report provides thorough insights on epidemiology and market trends.

• Multiple Sclerosis Market Analysis 

DelveInsight's Multiple Sclerosis- Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed understanding of historical and forecasted epidemiology. 

• Chronic Wounds Market 

DelveInsight's Chronic Wounds Market Insights, Epidemiology and Market Forecast - 2030 report provides detailed insights on historical and forecasted epidemiology.

• Smoking Cessation Market Analysis 

DelveInsight's Smoking Cessation - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology.

•  Radiation Toxicity Market Analysis 

DelveInsight's Radiation Toxicity Market Insights, Epidemiology and Market Forecast - 2030 report provides an in-depth understanding of historical and forecasted epidemiology. 

• Indolent Lymphoma Market Analysis 

DelveInsight's Indolent Lymphoma - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology.

• ICOS-Next Generation Immunotherapy Competitive Landscape and Market Forecast Analysis 

DelveInsight's 'ICOS-Next Generation Immunotherapy- Competitive Landscape and Market Forecast–2035' report delivers an in-depth understanding of the ICOS as well as the market trends.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. 

Contact Us:
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg